Results for "del-desiran"

Novartis stock dropped sharply after announcing that its experimental treatment for a rare muscular disease missed its primary endpoint in a late-stage clinical trial. The failure marks the third consecutive development setback for the pharmaceutical giant, raising concerns over its future pipeline and investor confidence.